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ABSTRACT 
Background: ATTRV30M amyloidosis is a lethal autosomal dominant sensorimotor and 
autonomic neuropathy caused by amyloid deposition composed of aggregated misfolded TTR 
monomers with the V30M mutation. The age of onset in patients with ATTRV30M varies in 
different foci and the mechanism behind it is still unknown.  
Methods: The tertiary neurology center following all ATTRV30M patients in Cyprus was used 
to collect demographic data to estimate; prevalence, incidence, penetrance, anticipation, time 
from disease onset to diagnosis and transplantation. Ocular, cardiac and leptomeningeal 
involvement in transplanted patients was explored. Correlation of C1q tagging SNPs with age of 
disease onset was carried out. 
Results: Prevalence and incidence for ATTRV30M neuropathy in Cyprus are 5.4/100,000 and 
0.3/100,000 respectively. Mean age of onset is 40.6 years and anticipation is 8.3 years. 
Penetrance reaches 51% and 75% by the ages of 50 and 80 years respectively. In liver 
transplanted patients rates of ocular, cardiac and leptomeningeal involvement were estimated to 
be 60%, 20% and 16% respectively. C1q polymorphisms correlated with age of disease onset. 
Conclusion: ATTRV30M neuropathy has a rising prevalence in Cyprus due to improved survival 
of patients. Late onset complications are becoming a major problem. Complement C1q appears to 
be a modifier in this disease. 
Keywords  
Epidemiology; ATTRV30M; neuropathy; complement; C1q; Cyprus 
List of Abbreviations: ATTRm: Hereditary transthyretin amyloid protein; ATTRV30M: 
hereditary transthyretin amyloid protein with V30M mutation; CI: confidence interval; 
CING: Cyprus Institute of Neurology and Genetics; CMAP: compound muscle action 
potential; HR: hazard ratio; HWE: Hardy–Weinberg equilibrium; LT: liver 
transplantation; SNAP: sensory nerve action potential; SNPs: single nucleotide 
polymorphisms; TFNEs: transient focal neurological episodes; TTR: transthyretin 
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Introduction 
Hereditary transthyretin (ATTRm) amyloidosis  may give rise to a peripheral neuropathy  
where extracellular mutated transthyretin (TTR) is deposited, predominantly in the 
peripheral nerves, heart and renal tissues [1]. It is an autosomal dominant disorder caused 
by the substitution of valine by methionine at position 30 [2]. Generally considered to be 
a progressive and fatal disease with autonomic and sensorimotor symptoms. ATTRV30M 
neuropathy has an average survival of 10 years after diagnosis and until recently the only 
available treatment was orthotopic liver transplantation (LT) [3, 4].  
The original cases of ATTRV30M neuropathy were recorded in Portugal [1], followed by 
reports in Sweden and Japan [5, 6] which are large endemic areas with families carrying 
single genetic mutations [7]. Smaller endemic foci have been reported in Majorca and 
Cyprus [8, 9]. Recent studies have also reported late onset ATTR V30M amyloidosis 
cases with distinct clinical phenotype in non-endemic areas [10]. ATTRm neuropathy is 
highly heterogeneous, both genetically and phenotypically [11] and ATTRV30M is the 
most common ATTRm neuropathy diagnosed in Portugal, Brazil and Sweden [7]. In 
France and Japan, around 30 different TTR mutations have been detected [12-14]. An 
epidemiological study performed in 2003 in the Cypriot population recorded a total of 36 
patients from 22 ATTRV30M families. The average age of onset was found to be 48.6 
years with the most common initial symptom being neuropathic foot pain. Also, the study 
reported positive anticipation independent of the transmitting parents’ sex.  
Penetrance and age of onset are variable among different populations. Epigenetic and 
genetic factors are believed to contribute to this variability. In search of modifier genes 
our group has examined the role of the complement pathway, since complement factors 
have been found to co-precipitate with amyloid in various forms of amyloidotic 
neuropathy [15]. Certain polymorphic sites in C1q were previously found to correlate 
with the age of onset in Cypriot patients suggesting that complement C1q may indeed be 
a modifier [16]. Data from our group suggest that C1q ablation in TTRKO/Met30
+/+ 
transgenic mice enhances amyloid deposition, while upregulating apoptosis and oxidative 
stress [17, 18]. 
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Epidemiology of this disease is evolving; patients are now diagnosed earlier and are 
offered more treatments. In the current study we report epidemiologic data, 15 years after 
the initial follow-up of the previous study [9] and we re-evaluate the impact of C1q on 
the age of onset in a greater cohort. 
 
Materials and Methods 
Epidemiological and demographic data 
Demographic data were collected on all patients diagnosed at the Cyprus Institute of 
Neurology and Genetics (CING). The CING is the only tertiary neurology center in 
Cyprus where all patients with ATTRV30M neuropathy are referred to for molecular 
diagnosis and clinical management including referral for LT and other treatments. All 
cases of ATTRV30M neuropathy in Cyprus are strictly familial. The small size of the 
total population and the closeness of Cypriot families ensure complete ascertainment of 
symptomatic cases. The data collected for each patient or carrier included current age, 
sex, place of residence, place of origin, age at onset of symptoms, type of symptoms at 
presentation, time to diagnosis, duration of illness and age at death. Genetic counselling 
was also provided. Furthermore, a timeline to transplantation was also constructed based 
on the patients’ files. The census date used for estimating prevalence and incidence of 
ATTRV30M amyloidosis within the population of Cyprus is 31/12/2016. Patients are 
defined as carriers of the V30M mutation who are symptomatic, while carriers simply 
have the mutation but no relevant symptoms. The patients were diagnosed by genetic 
testing, typical clinical phenotype and a biopsy (either rectal, abdominal fat or peripheral 
nerve). All transplanted patients and all patients receiving Tafamidis had to have a 
positive biopsy prior to treatment. In patients who have had liver transplantation (all in 
the UK) the results were not always available; however in 23 patients the biopsy results 
were available. 
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Neurophysiological assessment 
Sensory and sensorimotor axonal neuropathies are defined as length dependent 
neuropathies involving only sensory or sensory and motor axons respectively, (normal 
values; sural SNAP>6.0µV, CV>44m/s, peroneal EDP CMAP>4mV, CV>42m/s, tibial 
AHL CMAP> 5mV, CV>41m/s. Mild demyelination was defined as slowing of 
conduction velocities out of proportion to CMAP values but not fulfilling the diagnostic 
criteria of chronic demyelinating neuropathy. Normal conduction was defined as a result 
within the amplitude and conduction velocities of our lab.    
Leptomeningeal involvement 
Leptomeningeal involvement was diagnosed either from history of transient focal 
neurological episodes () and/or the presence of microhaemorrahges on T2-gradient echo 
sequence (GRE) magnetic resonance imaging. TFNEs were defined as transient motor 
and/or sensory and/or speech disturbances of variable onset and duration. Typically they 
did not have the instantaneous onset of transient ischemic attacks.   
Ocular and cardiac involvement 
The following abnormalities were considered as evidence of ocular involvement; 
keratoconjunctivitis sicca, abnormal conjunctival vessels, anterior chamber amyloid 
deposits, vitreous amyloid deposits, abnormal shape of the iris and amyloid deposits, 
presence of intraocular hypertension and lid abnormalities. 
The following abnormalities were considered as evidence of cardiac involvement; end-
diastolic interventricular thickness of >12mm, reduced longitudinal function with tissue 
Doppler Imaging ( e´ , a´ and s´ < 5cm/second and absolute longitudinal strain < 15%),  
preserved radial and apical function and sparkling texture. 
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Candidate gene approach 
Signed informed consent from 44 patients and 14 carriers seen in the last 12 months were 
obtained followed by blood collection. DNA samples from 80 patients (deceased 
included) and 19 carriers were available to be assessed for 21 C1q tagging SNPs. A 
corresponding number of age matched controls was also assessed for the same SNPs, in 
order to assess their minor allele frequencies and establish Hardy–Weinberg equilibrium 
status. Nineteen (19) SNPs were assessed by a standardized allelic discrimination 
protocol using real time-PCR for all patients/carriers and the corresponding number of 
age matched controls. Two SNP assays rs15940 and rs17433222 (no longer industrially 
produced) were assessed via the conventional PCR/sequencing protocol. Approval from 
the Cyprus Bioethics Committee was obtained for the study whereby the consent forms 
and subsequent protocols followed were accepted (Cyprus National Bioethics Committee 
- ΕΕΒΚ/ΕΠ /2015/36) 
Statistical analysis  
Age specific penetrance was estimated by a modified segregation retrospective likelihood 
analysis [19, 20] to account for the non-random ascertainment of carriers with respect to 
their disease phenotype, using the MENDEL software [21]. Anticipation was estimated 
based on the age of onset in a pool of available offspring-parent pairs and its statistical 
significance was tested by a paired t-test. The number of potential asymptomatic carriers 
was estimated from 31 families taking into account that the disease is autosomal 
dominant exhibiting a 50% probability of inheritance. Statistical significance of the mean 
age of onset between ATTRV30M patients was evaluated via the two-sample t-test. The 
p-value threshold, which is used to indicate the statistical significance, was set to values 
lower than 0.05 (p<0.05).  
Concerning SNPs analysis two different statistical tests were performed. In the first test, 
considering both symptomatic and asymptomatic carriers (19 asymptomatic /80 patients), 
the age of onset was used as the initial start point for the patients and the age of last 
healthy observation was used for asymptomatic carriers. The second test was performed 
in respect to age of onset and included only patients (80 cases). The Cox proportional 
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hazards model was carried out, where the event was defined as the age of onset. Analyses 
were performed in R (coxph) using cluster analysis where variance was adjusted to 
account for ascertainment bias due to the fact that data was only collected from affected 
families. 
 
Results 
Number of patients 
On the 31
st
 of December 2016, 46 living ATTRV30M patients were recorded in Cyprus 
(24 males and 22 females). Since the late 1980s and until the 31
st
 of December 2016, 82 
patients were formally diagnosed in Cyprus with ATTRV30M neuropathy. All patients 
originated from 31 families, 14 families from Kyrenia, 14 from Limassol and 3 from 
Paphos. All patients were of Greek- Cypriot descent.   
Out of the 46 living patents, 36 had been transplanted. Three patients were on TTR 
stabilizers and three patients had been referred to start a stabilizer. Three patients were 
participating in a Phase 3 trial of an anti-sense oligonucleotide and one patient was at 
stage III neuropathy and was receiving supportive treatment.  
Prevalence 
The prevalence was estimated based on the official population census of 31/12/2016. The 
total population in the republic of Cyprus on that date was 854,800. 46 living 
ATTRV30M patients were recorded in Cyprus. Thus, the prevalence of ATTRV30M 
neuropathy was estimated to be 5.4/100,000. Prevalence at the risk population (over the 
age of 18) was estimated to be 6.4/100,000. 
Incidence  
During the period 2003-2016, 31 patients were diagnosed with ATTRV30M amyloidosis 
in Cyprus. The average annual incidence was estimated as 0.3/100,000 of the total 
population. 
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Anticipation 
The anticipation of ATTRV30M amyloidosis was estimated based on the age of onset of 
49 patient pairs of offspring-parents and was derived from a pool of 82 patients.  
The mean age of onset in parents was 50.3 years and 40.7 years in offspring (p-value: 
9.23x10
-7
, paired t-test). Thus, positive anticipation was recorded, where the age of onset 
in the offspring was on average 9.6 years earlier than their respective affected parent. The 
sex of the transmitting parent did not appear to influence anticipation (p-value: 0.54, two-
sample t-test). Also, the anticipation for 23 offspring-parent pairs (where the offspring 
manifested between 2003 and 2016), was assessed. In this group the offspring were 
diagnosed 8.3 years earlier than their transmitting parent (p-value: 2.73x10
-5
, paired t-
test).  
Estimation of asymptomatic carriers 
Potential carriers were identified through their re-visited pedigrees. Of the 259 potential 
carriers estimated, 215 were over the age of 18. Therefore, the prevalence of 
asymptomatic carriers was estimated to be 30.3/100,000 and 30/100,000 over the age of 
18.  
Penetrance 
Fig 1a illustrates the estimated penetrance by age. It is obvious that penetrance appears to 
be age related. At the age of 20 years the risk of developing the disease is 6%, whereas 
the risk at ages of 50 and 80 increases to 51% and 75% respectively.    
Mean age of onset 
The mean age of onset (mean ± SD) of all patients diagnosed in Cyprus until 31/12/2016 
was estimated to be 44.5 ±15 (n=82), in males 43.8±16 (n=40) and 45.2±15 (n=42) in 
females (no statistical difference recorded, p-value: 0.68, two-sample t-test). The mean 
age of onset in live patients on 31/12/2016 was 40.6±12 (n=46) (Fig 1b), while in patients 
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which manifested between 2003 and 2016 it was 41.4±14 (n=29). The mean period from 
onset to diagnosis in live patients was 18.5 months (n=46).  
From the late 1980’s until 31/12/2016, 53 ATTRV30M carriers were confirmed (five 
died asymptomatic). The mean age of live carriers (n=48) was estimated 47.5±15, which 
does not differ significantly (p-value: 0.27, two-sample t-test) compared to all 
ATTRV30M patients (n=82). 
Phenotype 
Symptoms at onset 
The initial presenting symptoms of the 46 living patients are summarized in Table 1. The 
most commonly reported initial symptoms were “sharp shooting” or “burning” pains 
(74%) and the most commonly observed sign was dissociated sensory loss (96%).  
 
Neurophysiological testing at diagnosis 
Nerve conduction studies at diagnosis were performed for 43 patients. Sensorimotor 
axonal neuropathy was detected in 25 patients (58%), whereas 11 patients (26%) had 
sensory axonal neuropathy. Only one patient (2.3%) was diagnosed with mild 
demyelination and six patients (14%) had normal nerve conduction.  
Amyloid deposits at diagnosis 
Biopsy results at diagnosis were available for 23 ATTRV30M patients: 14 patents (61%) 
were rectal positive, two patients (9%) rectal negative, two sural nerve positive (9%), two 
abdominal fat positive (9%), one cardiac muscle positive (4%), one patient both rectal 
and abdominal fat positive (4%) and another one was both urinary bladder and abdominal 
fat positive (4%). SAP scan results were available for 21 patients: 15 were positive (71%) 
and 6 were negative (29%).  
Liver transplantation 
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Thirty-six from the 46 living patients underwent orthotopic liver transplantation (LT). 
The mean period from symptom onset to transplantation was 37.3 months and from 
diagnosis to transplantation was 18.6 months. Serum albumin levels at transplantation 
were only available for 31 patients and their estimated average was 40.7g/L (normal 35-
50 g/L). All patients were in Stage I neuropathy.  
Leptomeningeal involvement in transplanted patients 
Six transplanted patients (17%) displayed leptomeningeal involvement: one subclinical 
(positive MRI), five had TFNEs (Focal Neurological Episodes). MRI was performed in 
four patients without a pacemaker; two were normal and two abnormal. CT scans were 
performed on 10 patients but were found to be normal in all cases.  
Ocular and cardiac involvement in transplanted patients 
Ocular and cardiac involvement was also assessed in transplanted patients. Ocular 
assessment was carried out on 32 of the patients. Nineteen were found to be positive 
(59%), while 13 were negative (41%) for ocular involvement.  
Twenty nine transplanted patients have had repeated echocardiography assessments and 
six were found to have cardiac involvement (21%). None presented with 
cardiomyopathy.  
 
Candidate gene approach to assess for disease modifiers-SNPs analysis  
Eighty patients (44 alive and 36 deceased), 19 carriers– both classified as “cases” and 99 
controls (wild type TTR) were analyzed. The Hardy–Weinberg equilibrium (HWE) was 
calculated for all SNPs in the control population (Supplementary Table 1). SNPs 
rs186037 and rs294223 did not follow the Hardy–Weinberg equilibrium (HWE p-value 
threshold: 0.05) and were thus excluded from further analysis.  
Using both asymptomatic and symptomatic carriers (19 asymptomatic/80 patients) and by 
using age of onset as the time point for the patients and the age of last healthy 
observation for the asymptomatic carriers we performed Cox proportional hazards 
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analysis with the  event being the age of onset or the age of last healthy observation. We 
performed the analyses in R (coxph), estimating the cluster robust variance on family to 
account for the fact that we have data from relatives. The hazard ratio (HR) and 
confidence interval (CI) can be potentially biased as we do not take into account the non-
random ascertainment of the samples in the study. The results below assess the modifying 
effect of each SNP to the disease.  HR was calculated in respect to the major allele 
(Supplementary Table 2). 
In the first statistical test, the most significant modifying effect association came from 
rs672693 (p-value: 5.87x10
-3
, HR: 1.63, 95% CI: 1.15-2.30) whereas the two SNPs 
(rs9434, rs294180) correlated strongly with age of onset while rs665691 and rs12126436 
were also moderately associated. Therefore, allele G of rs672693 increases the risk of 
manifesting ATTRV30M amyloidosis earlier.   
In respect to the age of onset when using patients only (80 cases) the most significant 
modifying effect came from rs665691 (p-value: 1.87x10
-3
, HR: 1.54, CI: 1.17-2.03) and 
the others that were significantly associated with it. Thus, earlier age of onset is 
associated with allele C of rs665691 in the Cypriot patients. The entire squared 
correlation coefficient table amongst the tested SNPs in the carriers’ pool can be found in 
supplementary table 3.  
 
Discussion 
 
Prevalence in other endemic areas such as Northern Portugal, Northern Sweden and 
Nagano, Japan is estimated to be 163.1 in 100,000, 104 in 100,000 and 1.29 in 100,000 
population respectively [22] Also, the age of onset varies across different endemic areas. 
The mean age of onset in Portuguese and Japanese ATTRm patients is 33 years [23, 24], 
while in Swedish patients the mean age of onset is 56 years of age [25]. Disease 
anticipation has also been reported in most endemic countries such as Portugal, Sweden 
and Japan [26-29] 
 
The currently estimated prevalence of ATTRV30M neuropathy in Cyprus is 5.4/100,000, 
compared to the 2003 value of 3.7/100,000 [9]. This increase in prevalence is accounted 
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for by the increase in the number of living patients. New manifesting carriers are 
diagnosed and referred for LT earlier and survive longer. Currently, there are 46 living 
patients compared to the 27 included in the previous study. Also, increased awareness 
within the families themselves facilitates earlier diagnosis. The average incidence 
recorded between 2003 and 2016 appears to be lower (0.3/100,000) compared to the 
1992-2002 average (0.7/100,000). This is may be partly due to a larger pool of 
undiagnosed patients that were diagnosed during 1992-2002.  
 
Penetrance of the disease may also impact the incidence assuming a continuous pool of 
carriers. The biological basis of penetrance is poorly understood and both by genetic and 
environmental factors are involved. In the current study, we estimated the penetrance of 
ATTRV30M neuropathy in Cyprus to be 51% and 75% at the ages of 50 and 80 years 
respectively. In France, 18% and 85% respectively, 69% and 85% in Portugal [30] and 
11% and 69% in Sweden [28].  
 
The mean age of symptom onset was 41.4±14 years compared to 48.6±15 years in the 
previous survey. Additionally, we confirm that the patients’ sex does not influence the 
age of onset in Cypriot patients [9], as similarly observed in the Swedish population [23]. 
This is in contrast to both the Portuguese and Brazilian populations where the patients’ 
sex does influence the age of onset [26, 31].   
Anticipation was found to remain unchanged and may explain the approximately 8 year 
reduction in the age of onset in the current study, although earlier diagnosis is possible. 
Mean period from symptom onset to diagnosis was 18.5 months, largely due to patient 
denial, failure of non-specialists to recognize the disease, as well as the criterion for 
diagnosis at the CING where the presence of dissociated sensory loss is required. 
The phenotype of the patients in both surveys followed the typical pattern of small fiber 
and autonomic neuropathy. Also, no patients with demyelinating neuropathy were 
identified (most common ATTRV30M misdiagnosis). It is our current practice to 
diagnose the presence of ATTRV30M neuropathy when dissociated sensory loss is 
present on clinical examination. In all patients tissue confirmation of amyloidosis was 
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required. Leptomeningeal involvement was present in about 16% of the post transplanted 
patients, who also had ocular amyloid disease.  
The genetic analysis has found that C1q SNPs rs665691, rs158761, rs172378, rs672693, 
rs9434 and rs294180 correlate with an earlier age of disease onset. C1q activates the 
classical complement pathway ultimately producing the potent C5a anaphylatoxin, which 
in turn activates phagocytic cells and induces clearance of TTR amyloid deposits [32].  
SNP rs665691 (allele C) was found to be one of the most significant associations. 
According to dbSNP-NCBI, rs665691 is found among microRNA 6127 (MIR6127), 
which is located on 1p36.12. Interestingly, this SNP is also found to be significantly 
associated (P = 0.0006) with the risk of developing rheumatoid arthritis in a cohort of 822 
patients and over 1000 controls [33].     
 
SNP rs672693 (allele G) was also to have a significant modifying effect in the test 
involving the combined TTRV30M carrier analysis, although it was also found to be 
significant in the analysis including only patients. SNP rs672693 is located within an 
intronic region of C1qC chain and may be involved in splicing. Polymorphisms within 
intronic regions may alter splicing and gene transcription [34].  
Genetic variants of other complement components have previously been shown to act as 
modifiers of both the onset and the expression of ATTRm amyloidosis, more specifically 
the C3F and C4A3 variants were found to be significantly higher in early onset patients 
[35].  
The correlation of C1q polymorphisms and age of onset of ATTRV30M neuropathy may 
or may not be a causative association. There are some human and animal data that 
provide evidence consistent with a pathogenic role for complement in amyloid 
neuropathy. Nerve biopsies of patients with amyloidotic neuropathy show co-
precipitation of complement with amyloid [15, 36]. C1q ablation in the ATTRV30M 
neuropathy mouse model exacerbates amyloid deposition while complement C5a 
agonists stimulate phagocytosis and reduce amyloid deposits [18, 32]. It is therefore 
likely the C1q polymorphisms have a causative association with age of onset. 
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Furthermore, studies in lupus and rheumatoid arthritis have shown that the expression 
levels of C1q and other complement components significantly change depending on the 
polymorphism expressed, thus affecting the overall function of the complement cascade 
[37, 38].     
In the current study an increased prevalence of 5.4/100,000 for ATTRV30M was 
recorded in Cyprus, mainly accounted for by improved survival due to LT. We have 
confirmed that the phenotype of the disease remains largely that of the typical length-
dependent sensorimotor and autonomic neuropathy. No sporadic cases were recorded. 
We confirm the presence of positive anticipation of about 8 years and an age specific 
penetrance different from other endemic foci. Additionally, we have demonstrated a 
number of C1q tagging SNPs associated with age of onset supporting a modifier role for 
C1q which need to be replicated in other populations. 
 
Disclosure statement: The authors report no conflicts of interest. 
Funding: This work was supported by Telethon Cyprus and Pfizer’s GLOBAL Aspire 
Grants. 
 
References 
[1] Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized 
amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75:408-27.  
 
[2] Saraiva MJ, Birken S, Costa PP, et al. Amyloid fibril protein in familial amyloidotic 
polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin 
(prealbumin). J Clin Invest. 1984;74:104-19. 
[3] Conceicao I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy 
(Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve. 
2007;35:116-8.  
 
[4] Koike H, Tanaka F, Hashimoto R, et al. Natural history of transthyretin Val30Met familial 
amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol 
Neurosurg Psychiatry. 2012;83:152-8.  
 
[5] Andersson R. Familial amyloidosis with polyneuropathy. A clinical study based on 
patients living in northern Sweden. Acta Med Scand Suppl. 1976;590:1-64. 
 
[6] Araki S, Mawatari S, Ohta M, et al. Polyneuritic amyloidosis in a Japanese family. Arch 
Neurol. 1968;18:593-602.  
Page 15 of 22
URL: http://mc.manuscriptcentral.com/damy
Amyloid
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
15 
 
15 
 
 
[7] Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 
2011;10:1086-97. 
 
[8] Reines JB, Vera TR, Martin MU, et al. Epidemiology of transthyretin-associated familial 
amyloid polyneuropathy in the Majorcan area: Son Llatzer Hospital descriptive study. 
Orphanet J Rare Dis. 2014;9:29.  
 
[9] Dardiotis E, Koutsou P, Papanicolaou EZ, et al. Epidemiological, clinical and genetic study 
of familial amyloidotic polyneuropathy in Cyprus. Amyloid. 2009;16:32-7.  
 
[10] Koike H, Misu K, Ikeda S, et al. Type I (transthyretin Met30) familial amyloid 
polyneuropathy in Japan: early- vs late-onset form]. Arch Neurol. 2002;59:1771-6.  
[11] Reilly MM, Adams D, Booth DR, et al. Transthyretin gene analysis in European patients 
with suspected familial amyloid polyneuropathy. Brain. 1995;118:849-56. 
 
[12] Araki S, Ando Y. Transthyretin-related familial amyloidotic polyneuropathy-Progress in 
Kumamoto, Japan (1967-2010). Proc Jpn Acad Ser B Phys Biol Sci. 2010;86:694-706. 
 
[13] Plante-Bordeneuve V, Lalu T, Misrahi M, et al. Genotypic-phenotypic variations in a 
series of 65 patients with familial amyloid polyneuropathy. Neurology. 1998;51:708-14. 
 
[14] Ikeda S, Takei Y, Tokuda T, et al. Clinical and pathological findings of non-Val30Met TTR 
type familial amyloid polyneuropathy in Japan. Amyloid. 2003;1:39-47. 
 
[15] Hafer-Macko CE, Dyck PJ, Koski CL. Complement activation in acquired and hereditary 
amyloid neuropathy. Journal of the peripheral nervous system : JPNS. 2000;5:131-9.  
[16] Dardiotis E, Koutsou P, Zamba-Papanicolaou E, et al. Complement C1Q polymorphisms 
modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. J Neurol Sci. 
2009;284:158-62.  
 
[17] Pisalyaput K, Tenner AJ. Complement component C1q inhibits beta-amyloid- and serum 
amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J 
Neurochem. 2008;104:696-707.  
 
[18] Panayiotou E, Fella E, Papacharalambous R, et al. C1q ablation exacerbates amyloid 
deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy. 
PloS one. 2017;12:e0175767.  
 
[19] Antoniou AC, Sinilnikova OM, Simard J, et al. RAD51 135G-->C modifies breast cancer 
risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am 
J Hum Genet. 2007;81:1186-200. 
[20] Barnes DR, Lee A, Investigators E, et al. Evaluation of association methods for analysing 
modifiers of disease risk in carriers of high-risk mutations. Genet Epidemiol. 
2012;36:274-91. 
 
Page 16 of 22
URL: http://mc.manuscriptcentral.com/damy
Amyloid
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
16 
 
16 
 
[21] Lange K, Weeks D, Boehnke M. Programs for Pedigree Analysis: MENDEL, FISHER, and 
dGENE. Genet Epidemiol. 1988;5:471-2.  
 
[22] Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence 
of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57:829-837.  
 
[23] Sousa A, Andersson R, Drugge U, et al. Familial amyloidotic polyneuropathy in Sweden: 
geographical distribution, age of onset, and prevalence. Hum Hered. 1993;43:288-94.  
 
[24] Ikeda S, Nakazato M, Ando Y, et al. Familial transthyretin-type amyloid polyneuropathy 
in Japan: clinical and genetic heterogeneity. Neurology. 2002;58:1001-7.  
[25] Holmgren G, Costa PM, Andersson C, et al. Geographical distribution of TTR met30 
carriers in northern Sweden: discrepancy between carrier frequency and prevalence 
rate. J Med Genet. 1994;31:351-4.  
 
[26] Sousa A, Coelho T, Barros J, et al. Genetic epidemiology of familial amyloidotic 
polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal). 
Am J Med Genet. 1995;60:512-21.  
 
[27] Drugge U, Andersson R, Chizari F, et al. Familial amyloidotic polyneuropathy in Sweden: 
a pedigree analysis. J Med Genet. 1993;30:388-92.  
 
[28] Hellman U, Alarcon F, Lundgren HE, et al. Heterogeneity of penetrance in familial 
amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid. 
2008;15:181-6. 
 
[29] Yamamoto K, Ikeda S, Hanyu N, et al. A pedigree analysis with minimised ascertainment 
bias shows anticipation in Met30-transthyretin related familial amyloid polyneuropathy. 
J Med Genet. 1998;35:23-30.  
 
[30] Plante-Bordeneuve V, Carayol J, Ferreira A, et al. Genetic study of transthyretin amyloid 
neuropathies: carrier risks among French and Portuguese families. J Med Genet. 
2003;40. 
 
[31] Bittencourt PL, Couto CA, Clemente C, et al. Phenotypic expression of familial amyloid 
polyneuropathy in Brazil. Eur J Neurol. 2005;12:289-93. 
 
[32] Fella E, Sokratous K, Papacharalambous R, et al. Pharmacological stimulation of 
phagocytosis enhances amyloid plaque clearance; evidence from a transgenic mouse 
model of ATTR neuropathy. Front Mol Neurosci. 2017;10. 
 
[33] Trouw LA, Daha N, Kurreeman FA, et al. Genetic variants in the region of the C1q genes 
are associated with rheumatoid arthritis. Clin Exp Immunol. 2013;173:76-83.  
 
[34] Jo BS, Choi SS. Introns: The functional benefits of introns in genomes. Genomics Inform. 
2015;13:112-8.  
 
Page 17 of 22
URL: http://mc.manuscriptcentral.com/damy
Amyloid
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
17 
 
17 
 
[35] Nylander PO, Beckman L, Holmgren G, et al. Association of C3 and C4A complement 
types with familial amyloidotic polyneuropathy. Hum Hered. 1990;40:272-7.  
 
[36] Zanusso GL, Moretto G, Bonetti B, et al. Complement neoantigen and vitronectin are 
components of plaques in amyloid AL neuropathy. Ital J Neurol Sci. 1992;13:493-9. 
 
 
[37] Rafiq S, Frayling TM, Vyse TJ, et al. Assessing association of common variation in the C1Q 
gene cluster with systemic lupus erythematosus. Clin Exp Immunol. 2010;161:284-9.  
 
[38] Liphaus BL, Umetsu N, Jesus AA, et al. Molecular characterization of the complement 
C1q, C2 and C4 genes in Brazilian patients with juvenile systemic lupus erythematosus. 
Clinics. 2015;70:220-7.  
 
 
 
Tables 
Table 1:  Initial symptoms and signs among Cypriot ATTRV30M patients. 
Initial symptoms Number of Patients % 
“Sharp shooting” or “burning” pains 34/46 74% 
Nausea, vomiting, early satiety 16/46 35% 
Diarrhea 5/46 11% 
Constipation 19/46 41% 
Impotence 6/46 13% 
Bladder disturbances 10/46 22% 
Sweating abnormalities 0/46 0 
Musculoskeletal (charcot joint) 1/46 2% 
Dissociated sensory loss 44/46 96% 
Orthostatic hypotension 8/46 17% 
Esophageal reflux 2/46 4% 
Hydronephrosis 2/46 4% 
Loss of sensation in the feet 2/46 4% 
Bilateral median and ulnar neuropathy 1/46 2% 
Numbness in the feet 1/46 2% 
Painless burns in the feet 1/46 2% 
Note: Some patients presented with more than one symptom at the same time. 
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Figure Legend: 
Figure 1. Penetrance and age of disease onset. (a) The risk of developing the disease is 
shown to increase along with age. (b) The age of onset for living ATTRV30M patients in 
5 year intervals is presented here, whereas the mean age of onset was found to be 
40.6±12 (n=46). 
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Figure 1. Penetrance and age of disease onset. (a) The risk of developing the disease is shown to increase 
along with age. (b) The age of onset for living ATTRV30M patients in 5 year intervals is presented here, 
whereas the mean age of onset was found to be 40.6±12 (n=46).  
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Supplementary Table 1: Minor allele frequency of all SNPs tested for cases and controls. Maf – minor allele frequency, Allele 1- minor allele/ 
allele 2- major allele *SNPs did not follow the Hardy–Weinberg equilibrium and were excluded from analyses. 
SNP Alleles maf_cases maf_controls HWE_p_cases HWE_p_controls 
rs172378 G/A 0.38 0.38 0.86 0.10 
rs9434 A/C 0.40 0.35 0.40 0.38 
rs12126436 A/G 0.18 0.20 0.22 0.92 
rs209698 G/A 0.45 0.40 0.06 0.35 
rs12128546 G/T 0.27 0.25 0.31 0.87 
rs186037* G/A 0.20 0.25 0.21 0 
rs158761 A/C 0.39 0.38 0.92 0.05 
rs665691 G/C 0.38 0.38 0.44 0.06 
rs6690827 A/G 0.29 0.28 0.38 0.30 
rs12404537 T/C 0.21 0.17 0.02 0.86 
rs672693 A/G 0.38 0.33 0.09 0.05 
rs294180 A/C 0.41 0.35 0.31 0.25 
rs12040131 G/C 0.19 0.16 0.04 0.66 
rs7549747 C/T 0.44 0.34 0.75 0.05 
rs7549888 T/G 0.46 0.47 0.62 0.35 
rs17486657 T/C 0.21 0.29 0.68 0.55 
rs294222 C/G 0.34 0.37 0.96 0.35 
rs294223* T/C 0.22 0.30 0.97 0.04 
rs17433871 C/T 0.26 0.22 0.46 0.07 
rs15940 T/C 0.32 0.22 0.56 0.22 
rs17433222 A/G 0.24 0.22 0.09 0.84 
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Supplementary Table 2: Estimated hazard ratios for earlier age of onset using survival analysis. Statistical analysis 1 includes both patients and 
asymptomatic carriers. Statistical analysis 2 includes patients only. Estimated SNPs hazard risk ratios. Statistical analysis 1- 99 ATTRV30M 
carriers (19 non-manifesting carriers /80 cases), Statistical analysis 2- 80 ATTRV30M cases. HR – Hazard Ratio / 95% CI 95% Confidence 
Interval 
 Statistical analysis No.1                        
(99 ATTRV30M carriers) 
Statistical analysis No. 2                    
(80 ATTRV30M cases) 
SNP HR (95%CI) P-value HR (95%CI) P-value 
rs172378 1.33 (0.95-1.88) 0.10 1.51 (1.15-1.99) 2.81x10
-3
 
rs9434 1.53 (1.10-2.14) 0.01 1.44 (1.05-1.97) 0.02 
rs12126436 1.52 (1.06-2.18) 0.02 1.51 (1.01-2.26) 0.05 
rs209698 1.26 (0.96-1.66) 0.10 1.19 (0.89-1.59) 0.24 
rs12128546 1.37 (0.95-1.97) 0.09 1.34 (0.94-1.92) 0.11 
rs158761 1.28 (0.92-1.79) 0.14 1.53 (1.16-2.00) 2.24x10
-3
 
rs665691 1.45 (1.07-1.98) 0.02 1.54 (1.17-2.03) 1.87x10
-3
 
rs6690827 1.28 (0.90-1.81) 0.16 1.26 (0.89-1.79) 0.19 
rs12404537 1.29 (0.86-1.93) 0.22 1.18 (0.76-1.85) 0.46 
rs672693 1.63 (1.15-2.30) 5.87x10
-3
 1.54 (1.10-2.16) 0.01 
rs294180 1.51 (1.08-2.10) 0.01 1.43 (1.04-1.95) 0.03 
rs12040131 1.55 (0.87-2.74) 0.13 1.42 (0.86-2.36) 0.17 
rs7549747 1.26 (0.89-1.79) 0.19 1.53 (1.10-2.13) 0.01 
rs7549888 1.11 (0.84-1.47) 0.45 1.07 (0.74-1.55) 0.71 
rs17486657 0.92 (0.61-1.37) 0.67 0.90 (0.57-1.43) 0.66 
rs294222 0.76 (0.53-1.11) 0.15 0.68 (0.48-0.95) 0.03 
rs17433871 1.13 (0.78-1.64) 0.51 1.09 (0.79-1.51) 0.58 
rs15940 1.34 (0.91-1.96) 0.14 1.25 (0.94-1.65) 0.13 
rs17433222 1.23 (0.78-1.94) 0.38 1.31 (0.87-1.97) 0.20 
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Supplementary Table 3: The squared correlation coefficient between the tested SNPs in the carriers. 
SNP 
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rs172378 1 0.36 0.34 0.38 0.25 0.76 0.81 0.66 0.43 0.30 0.36 0.27 0.40 0.09 0.02 0.28 0.19 0.23 0.40 
rs9434 0.36 1 0.29 0.28 0.43 0.32 0.33 0.42 0.44 0.86 0.98 0.36 0.26 0.30 0.01 0.37 0.15 0.58 0.50 
rs12126436 0.34 0.29 1 0.38 0.66 0.28 0.30 0.38 0.64 0.29 0.28 0.22 0.07 0.16 0 0.10 0.06 0.23 0.34 
rs209698 0.38 0.28 0.38 1 0.53 0.44 0.45 0.19 0.34 0.32 0.28 0.18 0.20 0.06 0.01 0.16 0.07 0.21 0.25 
rs12128546 0.25 0.43 0.66 0.53 1 0.23 0.24 0.32 0.44 0.46 0.44 0.20 0.12 0.17 0 0.15 0.10 0.31 0.36 
rs158761 0.76 0.32 0.28 0.44 0.23 1 0.92 0.46 0.38 0.39 0.33 0.21 0.29 0.12 0 0.26 0.18 0.16 0.38 
rs665691 0.81 0.33 0.30 0.45 0.24 0.92 1 0.50 0.41 0.41 0.34 0.22 0.28 0.13 0 0.26 0.19 0.15 0.38 
rs6690827 0.66 0.42 0.38 0.19 0.32 0.46 0.50 1 0.57 0.35 0.43 0.36 0.27 0.18 0.01 0.19 0.31 0.31 0.54 
rs12404537 0.43 0.44 0.64 0.34 0.44 0.38 0.41 0.57 1 0.45 0.42 0.50 0.18 0.25 0 0.17 0.17 0.40 0.58 
rs672693 0.30 0.86 0.29 0.32 0.46 0.39 0.41 0.35 0.45 1 0.88 0.35 0.21 0.33 0.01 0.32 0.15 0.46 0.54 
rs294180 0.36 0.98 0.28 0.28 0.44 0.33 0.34 0.43 0.42 0.88 1 0.34 0.26 0.31 0.01 0.38 0.16 0.56 0.51 
rs12040131 0.27 0.36 0.22 0.18 0.20 0.21 0.22 0.36 0.50 0.35 0.34 1 0.41 0.23 0.08 0.19 0.39 0.26 0.62 
rs7549747 0.40 0.26 0.07 0.20 0.12 0.29 0.28 0.27 0.18 0.21 0.26 0.41 1 0.03 0.19 0.43 0.29 0.23 0.31 
rs7549888 0.09 0.30 0.16 0.06 0.17 0.12 0.13 0.18 0.25 0.33 0.31 0.23 0.03 1 0.35 0.48 0.14 0.13 0.26 
rs17486657 0.02 0.01 0 0.01 0 0 0 0.01 0 0.01 0.01 0.08 0.19 0.35 1 0.14 0.05 0 0.03 
rs294222 0.28 0.37 0.10 0.16 0.15 0.26 0.26 0.19 0.17 0.32 0.38 0.19 0.43 0.48 0.14 1 0.15 0.23 0.19 
rs17433871 0.19 0.15 0.06 0.07 0.10 0.18 0.19 0.31 0.17 0.15 0.16 0.39 0.29 0.14 0.05 0.15 1 0.05 0.27 
rs15940 0.23 0.58 0.23 0.21 0.31 0.16 0.15 0.31 0.40 0.46 0.56 0.26 0.23 0.13 0 0.23 0.05 1 0.31 
rs17433222 0.40 0.50 0.34 0.25 0.36 0.38 0.38 0.54 0.58 0.54 0.51 0.62 0.31 0.26 0.03 0.19 0.27 0.31 1 
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